Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-05-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-023-00859-x |